NCT03765476

Brief Summary

This study aims to detect how the Web-based program SALIENCE affects patients with alcohol-use Disorder in terms of craving, cognitive functions and risk of relapse.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started Jul 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Jul 2018Dec 2026

Study Start

First participant enrolled

July 1, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 5, 2018

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 29, 2025

Status Verified

April 1, 2025

Enrollment Period

8.5 years

First QC Date

October 23, 2018

Last Update Submit

April 28, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change in alcohol craving

    Visual Analogue Scale

    directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)

  • Change in attentional bias

    Dotprobe-Task (MacLeod, Mathews, \& Tata, 1986)

    directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)

  • Change in alcohol interference

    Alcohol Stroop Test (Brand, Leichsenring-Driessen, Beblo, Kremer, \& Driessen, 2009)

    directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)

  • Change in approach-avoidance tendencies

    Approach Avoidance Task (AAT) (R. W. Wiers et al., 2009)

    directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)

Secondary Outcomes (1)

  • Relapse

    90 days after study inclusion

Study Arms (2)

TAU

ACTIVE COMPARATOR

treatment as usual

Behavioral: TAU

TAU plus SALIENCE

EXPERIMENTAL

treatment as usual plus computer-based intervention "SALIENCE"

Behavioral: SALIENCEBehavioral: TAU

Interventions

SALIENCEBEHAVIORAL

3 computer-based training sessions with program "SALIENCE" per week over 3 weeks (see study description)

TAU plus SALIENCE
TAUBEHAVIORAL

treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.

TAUTAU plus SALIENCE

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age between 18 and 65
  • alcohol use disorder (DSM-5)
  • inpatient or part inpatient treatment
  • alcohol abstinence for at least 72 hours and maximum for three weeks
  • normal or correctable eyesight
  • Sufficient ability to communicate with the investigators, to answer questions in oral and written form
  • "Fully Informed Consent"
  • "Written Informed Consent"

You may not qualify if:

  • Withdrawal of the declaration of consent
  • severe internistic, neurological or psychiatric comorbidities
  • severe withdrawal symptoms (CIWA-R \> 7)
  • alcohol-intoxication (\> 0 ‰)
  • Pharmacotherapy with psychoactive substances within the last 14 days (except Clomethiazole or Benzodiazepines within the alcohol withdrawal treatment; treatment with these medications has to be completed within last 3 days)
  • Axis 1 disorder according to ICD-10 and DSM 5 (except tobacco use disorder and specific phobia within the last 12 months)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit

Mannheim, Baden-Wurttemberg, 68159, Germany

Location

Related Publications (1)

  • Weber A, Shevchenko Y, Gerhardt S, Hoffmann S, Kiefer F, Vollstadt-Klein S. Effectiveness of Reducing Craving in Alcohol Use Disorder Using a Serious Game (SALIENCE): Randomized Controlled Trial. JMIR Form Res. 2023 Nov 7;7:e42194. doi: 10.2196/42194.

MeSH Terms

Conditions

Alcoholism

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Sabine Vollstädt-Klein

    ZI Mannheim

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: one group receives add-on- intervention "SALIENCE"
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2018

First Posted

December 5, 2018

Study Start

July 1, 2018

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 29, 2025

Record last verified: 2025-04

Locations